Ciprofloxacin News and Research

RSS

Single-dose of anibiotic gel could provide easy and safe treatment for common childhood illness

A single-application bioengineered gel, squirted in the ear canal, could deliver a full course of antibiotic therapy for middle ear infections, making treatment of this common childhood illness much easier and potentially safer, finds a preclinical study led by Boston Children's Hospital in collaboration with investigators at Boston Medical Center and Massachusetts Eye and Ear.

15 Sep 2016

Scientists discover novel African types of Salmonella linked to blood poisoning and death

The first global-scale genetic study of Salmonella Enteritidis bacteria, which is a major cause of blood poisoning and death in Africa and food poisoning in the Western World, has discovered that there are in fact three separate types.

22 Aug 2016

FDA approves safety labeling changes for fluoroquinolone antibiotics

The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections.

27 Jul 2016

Emergence of multidrug-resistant salmonella strains increases burden of neglected diseases in Africa

"The affected countries will have a major problem if we do not manage to control salmonella bloodstream infections with new antibiotics such as ciprofloxacin," cautions Prof Jürgen May.

15 Jun 2016

Antibiotics may be linked to delirium and other brain problems

Antibiotics may be linked to a serious disruption in brain function, called delirium, and other brain problems, more than previously thought, according to a "Views and Reviews" article published in the February 17, 2016, online issue of Neurology, a medical journal of the American Academy of Neurology.

18 Feb 2016

Salvat, Lee's Pharmaceutical partner to market Duoxal ear drops in Greater China

Laboratorios SALVAT, S.A. and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited, jointly announced today the signing of an exclusive License and Supply Agreement for the marketing and distribution of Duoxal ear drops (patented combination solution of Ciprofloxacin and Fluocinolone Acetonide) in the People's Republic of China, Hong Kong S.A.R., Macau S.A.R., and Taiwan and an option to add Thailand to the contractual territory.

12 Jan 2016

Environmental contaminants contributing to increase in bacterial resistance

While the rapid emergence of antibiotic-resistant bacteria has prompted the medical community, non-profit organizations, public health officials and the national media to educate the public to the dangers of misusing and overusing antibiotics, the University of Georgia's J. Vaun McArthur is concerned that there's more to the problem than the misuse of common medications.

24 Dec 2015

Latest ENT research to be presented at AAO-HNSF's annual meeting

The latest research on hearing loss, head and neck cancers, sleep apnea and other otolaryngic topics will be presented in Dallas, TX, September 27-30, at the 2015 Annual Meeting & OTO EXPO? of the American Academy of Otolaryngology--Head and Neck Surgery Foundation (AAO-HNSF), the largest annual meeting of ear, nose, throat, head and neck physicians in the world.

9 Sep 2015

Updated data from PROCLAIM national patient registry presented at 51st ASCO

Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.

1 Jun 2015

1 in 5 nursing home residents with dementia harbor strains of drug-resistant bacteria

A new study found one in five nursing home residents with advanced dementia harbor strains of drug-resistant bacteria and more than 10 percent of the drug-resistant bacteria are resistant to four or more antibiotic classes. The research was published online today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

30 Apr 2015

International travelers bring multidrug-resistant shigellosis to the US

International travelers are bringing a multidrug-resistant intestinal illness to the United States and spreading it to others who have not traveled, according to a report released today by the Centers for Disease Control and Prevention (CDC).

3 Apr 2015

Simple rectal swab cultures can thwart drug-resistant E. coli in patients undergoing TRUSBx procedures

Some infections after prostate biopsy due to drug-resistant Escherichia coli can be thwarted by simple rectal swab cultures prior to the procedure. The cultures test for antibiotic-resistant E. coli, and the findings are used to direct the selection of antimicrobial prophylaxis used for the procedure, according to Rhode Island Hospital researchers.

9 Dec 2014

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

The U.S. Food and Drug Administration has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI).

24 Nov 2014

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204).

23 Sep 2014

TAXIS acquires novel antimicrobial drug candidates from Biota

TAXIS Pharmaceuticals, Inc. today announced the acquisition of a group of novel antimicrobial drug candidates from Biota Pharmaceuticals Inc. of Atlanta, GA.

11 Aug 2014

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm Corporation ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE).

23 Jun 2014

Ciprofloxacin News and Research

Single-dose of anibiotic gel could provide easy and safe treatment for common childhood illness

Scientists discover novel African types of Salmonella linked to blood poisoning and death

FDA approves safety labeling changes for fluoroquinolone antibiotics

Emergence of multidrug-resistant salmonella strains increases burden of neglected diseases in Africa

Antibiotics may be linked to delirium and other brain problems

Salvat, Lee's Pharmaceutical partner to market Duoxal ear drops in Greater China

Environmental contaminants contributing to increase in bacterial resistance

Latest ENT research to be presented at AAO-HNSF's annual meeting

Updated data from PROCLAIM national patient registry presented at 51st ASCO

1 in 5 nursing home residents with dementia harbor strains of drug-resistant bacteria

International travelers bring multidrug-resistant shigellosis to the US

Simple rectal swab cultures can thwart drug-resistant E. coli in patients undergoing TRUSBx procedures

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

TAXIS acquires novel antimicrobial drug candidates from Biota

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Review on effects of treating cholera with antimicrobial drugs

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm reports total revenue of $6.6 million for Q1 2014

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News